Antitrust challenge may force big pharma groups to rethink ‘pure play’ business models

Pharma: M&A strategy gets dose of bitter medicine

Medicines price gouger Martin Shkreli was one of a kind. But trustbusters have fresh reasons to feel cross with the pharma industry. The US Federal Trade Commission now frowns on its “rampant consolidation”.
One sign of a more interventionist approach is revived suspicion of vertical takeovers. These combine businesses throughout a single supply chain.
This story originally appeared on: Financial Times - Author:Faqs of Insurances